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Abstract
Hepatocyte nuclear factors 4 alpha (HNF4a) and 3 beta (HNF3b) are members of a group of liver-enriched
transcription factors (LETFs) that play important roles in regulating the replication of hepatitis B virus (HBV) and
liver inflammation. However, the relationship of the level of HNF4a and HNF3b with the severity of HBV-infected
liver diseases is unclear. In this study, liver tissue samples from different types of HBV patients were collected, and
HNF4a and HNF3b expression were detected by immunohistochemistry. The expression of HNF4a was significant
higher in patients with severe hepatitis B(SHB) than those with chronic hepatitis B(CHB) and liver cirrhosis(LC) (both
P < 0.05), but similar between patients with CHB and LC (P > 0.05). And the expression of HNF3b was similar
among patients with CHB, LC and SHB (P > 0.05 for all pairwise comparison). This suggests that the expression
level of HNF4a was different in patients with different outcome of HBV infection, high expression level of HNF4a
may correlate with occurrence of SHB
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Background
H e p a t i t i sBv i r u s( H B V )i n f e c t i o ni sas e r i o u sg l o b a l
health problem, with 2 billion people infected worldwide
[1], and it would lead to various clinical outcomes, ran-
ging from an asymptomatic carrier state (inactive HBV
carrier) to acute or chronic liver disease including
chronic hepatitis B (CHB), severe hepatitis B (SHB), liver
cirrhosis (LC) and hepatocellular carcinoma(HCC) [2].
Because of the lack of specific therapies, those patients
are at high risk of mortality [3]. Currently, HBV infection
has become the 10th cause of death worldwide, and
approximately 15-40% of those patients with CHB will
develop to end-stage liver disease including LC, SHB, or
HCC [1].
Outcomes of HBV infection are affected by both virus
(such as: virus variation, virus protein, virus genotype, etc.)
and host factors (such as: cellular immunity, cytokines,
apoptosis, etc.) [4-8], and evidence have showed that viral
replication is mainly correlated to the development or pro-
gression of diseases [2,4]. In fact, viral replication is not
only regulated by host factors [9], but also can cause
changes in the level and activity of host factors, which
would result to severe hepatic damage due to cell dysfunc-
tion. Hepatic nuclear factors (HNFs) are a group of impor-
tant host transcription factors that mainly reside in the
liver and regulate numerous liver-expressed genes [10].
One of our previous work suggested that HNF4a and
HNF3b likely participated in HBV replication in patients
with HBV infection, or that HBV replication may some-
how influence the expression of hepatocyte nuclear factor
4alpha (HNF4a)a n d3b e t a( H N F 3 b) in the liver [11].
Using cell culture and animal models, we also found that
HNF4a supports HBV replication in non-hepatic cells and
HNF3b inhibits HBV replication [12]. And in recent years,
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hotspot.
Recently some scholars using gene chip analyzed liver tis-
sue samples of HBV infected patients, and they found that
HBV infection could increase the transcription of HNF,
which may be related to the occurrence of liver injury [13].
So we hypothesized the interaction of HNFs and HBV tran-
scriptional regulation may play an important role in the
pathogenesis of disease progression. However, it is still
unclear whether the expression level of HNFs is correlated
to the clinical outcomes of HBV infection. In present study,
we studied the variation of HNF4a and HNF3b expression
in different types of hepatitis B, so as to investigate the cor-
relation of HNFs expression and disease severity.
Results
Liver specimens from 19 HBV infections with variety of
clinical outcomes were studied, comprised of 6 patients
with chronic hepatitis B (Group A), 6 patients with liver
cirrhosis (Group B) and 7 patients with severe hepatitis B
(Group C). The serum HBV DNA levels of those patients
were ranged from 3 to 5 log10 copies/mL, and its level
was comparable among group A, B and C. Detailed char-
acteristics of those patients were summarized in Table 1.
Expression levels of HNF4a
Expression of HNF4a was detected in all 19 specimens,
and the typical immunohistochemical images of HNF4a
in these groups were shown in Figure 1. The mean scores
of HNF4a were 4.29, 4.75 and 5.58 for specimens in
group A, B, and C, respectively (Table 2). Among those
groups, HNF4a scores was significant higher in group C
as compared with either group A or B (Both P <0 . 0 5 ) .
Though higher scores were also observed in group B, the
difference was not statistic significantly as compared with
group A.
These data showed that HNF4a expression was
increased significantly in patients with SHB, and sug-
gested that high expression of HNF4a may correlate
with occurrence of SHB
Expression levels of HNF3b
Expression of HNF3b was detected in all 19 samples, and
the typical immunohistochemical images of HNF3b in
these groups were shown in Figure 1. The mean scores of
HNF3b were 2.71, 2.33 and 2.50 for specimens in group
A, B, and C, respectively (Table 3). Though more scores
were observed in group A, but the difference was not sig-
nificant as compared with either group B or C. And the
difference of score between group B and C was also not
significant.
T h e s ed a t as h o w e dH N F 3 b expression was similar
between different groups, and suggested that the expres-
sion of HNF3b may not correlate with clinical outcomes
of HBV infections.
Discussion
Current study reported that abnormal expression of host-
related genes in hepatitis B patients played important
roles in the occurrence, development and prognosis of
liver damage [6], and those host-related genes mainly
were apoptosis and inflammation-associated genes
[14-16]. Recently some scholars using gene chip analyzed
liver tissue samples of HBV infected patients, and they
found that HBV infection increased the transcription of
many genes such as HNF4, retinoid X receptor and per-
oxisome proliferator-activated receptors (RXR/PPARs)
and CCAAT/enhancer binding protein (C/EBP), and so
Table 1 Demographic and clinical characteristics
CHB
(Group A)
LC
(Group B)
SHB
(Group C)
Number 66 7
Age, ys 42.67 45.50 36.86
Male/Female 6/0 4/2 4/3
HBeAg(+)/HBeAg(-) 0/6 1/5 0/7
HBV DNA, log10 copies/mL 3.60 3.55 3.29
Figure 1 The expression of HNF4a and HNF3bin liver tissue of
typical patients in three groups were shown. The scores of
HNF4a were higher in c1 as compared to a1 and b1; while the
scores of HNF3 were similar among a2, b2 and c2.
Table 2 Scores of the expression levels of HNF4a
CHB (Group A) LC (Group B) SHB(Group C)
Pat.1 2.5 4.5 6.0
Pat.2 4.5 5.0 6.0
Pat.3 5.0 5.0 6.0
Pat.4 4.5 5.0 6.0
Pat.5 4.0 4.5 4.5
Pat.6 5.0 4.5 5.0
Pat.7 4.5 - -
Mean 4.29
▲ 4.75
Δ 5.58
▲Δ
The symbol “▲” and “Δ” indicated significant difference between two groups
(p < 0.05)
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Page 2 of 5on [13may correlate with disease severity of HBV infec-
tions. In contrast, HNF3b expression was similar among
patients with different outcome of HBV infection, and it
suggested HNF3b expression was not associated with dis-
ease severity caused by HBV, though our previous work
showed HNF3b could inhibit HBV replication [was
higher in liver tissue of patients with SHB, while the
expression of HNF3b was similar among liver tissue of
patients with different clinical outcomes, and our find-
ings indicated that the expression level of HNF4a and
HNF3b in different HBV infections, and we found that
the expression of HNF4a ], which suggested the high
expression of those gene may be related to the occur-
rence of liver injury caused by HBV. In present study, we
observed the expression of HNF4a [17,18].
HNFs are a class of protein molecules that mainly exist
in liver and regulate liver-specific gene expression at tran-
scriptional level, and HNF4a is one of the most important
regulatory factors of HNFs [10]. It has been reported that
the over-expression of fibrinogen-like protein 2(fgl2) is
correlated with occurrence of SHB, and the gene promoter
of fgl2 would be combined and activated by HNF4a, and it
suggested that HNF4a may play an important role in the
occurrence of SHB [19]. Recently, we inhibited the expres-
sion of HNF4a in mice with acute liver failure induced by
lipopolysaccharide and D-Galactosamine, and we found
that the liver damage of mice with LF was alleviated and
mortality rate was significant decreased (unpublished
data). The findings from experimental data also indicated
that the over-expression of HNF4a was an important fac-
tor for the occurrence of liver failure, which was consistent
with the findings observed in liver tissue samples of
patients with SHB in present study.
I th a sr e p o r t e dt h a tH N Fc o u l db i n da n da c t i v a t et h e
four promoters of HBV genome, which is important for
the regulation of transcription and replication of HBV
[20]. So it is reasonable to infer that the correlation of
over-expression of HNF4a with severe hepatitis B may
associate with its effect on HBV. We previously analyzed
the incidence of mutations in HBV precore/basal core pro-
moter (BCP) in patients with SHB, and found combined
mutation of A1762T + G1764A (TA mutation) in HBV
precore/BCP region might be related to the aggravation of
chronic HBV infection(unpublished data), because of
enhanced transcription and replication capacity of HBV
[20]. Interesting, evidence showed that the binding site of
HNF4a on HBV also located in HBV precore/BCP region,
so TA mutation in this region may affect HNF4a on regu-
lation of HBV transcription and replication [20]. In fact,
the results from non-liver derived cell lines and HBV
replication mouse model (with/without HNF4a inhibition)
had confirmed that HNF4a supported high replication
level of TA mutation, [20] which may contribute to the
aggravation of hepatitis B. Considering the positive corre-
lation between HNF4a expression and HBV replication in
liver tissue of IHBV infections, and avoiding the interfer-
ence of HBV DNA level on HNF4a expression, only
patients with serum HBV DNA less than 5 log10 copies/
mL were included, and the mean level of HBV DNA was
comparable between each group in this study. Thus, we
believe our result is a credible finding.
In summary, our results suggested that the expression
level of HNF4a was different in patients with different
outcome of HBV infection, and high expression level of
HNF4a may correlate with occurrence of SHB.
Materials and methods
Study population
A total of 19 liver tissue samples from 19 patients were
obtained from Hepatobiliary Surgery Department and
Center of Infectious Diseases, West China Hospital of
Sichuan University, between 2007 and 2008. The clinical
outcomes of those samples were consisted of CHB
(group A, n = 6), LC (group B, n = 6) and SHB (group C,
n = 7).
All patients were positive for hepatitis B surface anti-
gen (HBsAg) for at least 6 months, were without co-
infection of human immune-deficiency virus (HIV) and
other hepatitis viruses(hepatitis A, C and E virus), and
were without auto-immune hepatitis, drug-induced
hepatitis, and liver damages caused by other etiologies.
The study protocol was conformed to the ethical
guidelines of the 1975 Declaration of Helsinki.
Preparation of integrated tissue slice slides
Two different types of liver tissue specimens were
obtained: wedge and needle biopsy specimens. The wedge
specimens (2 × 2 × 2 cm
3) were taken during open sur-
gery, and needle biopsy specimens were obtained by a
biopsy needle under ultrasound guidance. Liver specimens
were fixed in 10% formalin for 24 to 48 h and embedded
in paraffin.
For wedge specimens, a blank paraffin block was pre-
pared and used as the recipient for the tissue samples,
and a 2 mm punch needle was used to punch the donor
Table 3 Scores of the expression levels of HNF3b
CHB (Group A) LC (Group B) SHB (Group C)
Pat.1 2.5 1.5 3.0
Pat.2 2.0 3.0 3.0
Pat.3 2.0 1.0 1.5
Pat.4 4.5 0.5 1.5
Pat.5 3.0 5.5 1.0
Pat.6 3.0 2.5 1.0
Pat.7 2.0 - -
Mean 2.71 2.33 2.50
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ent blocks at a defined region according to the marker
made on blank paraffin block in advance. After all indi-
vidual specimens were integrated on a single paraffin
b l o c k ,t h ei n t e g r a t e dt i s s u ew a ss e c t i o n e da tas l i c e
thickness o f 4 mm. Sections were stretched in a 40°C
water bath, mounted a glass slides, and dried at 60°C for
2h .
For needle biopsy specimens, paraffin-embedded tissue
was sectioned at a slice thickness of 4 um. And all sec-
tions were stretched in a 40°C water bath and mounted
a glass slides at a defined region according to the mar-
ker made on the slide in advance. As a result, all tissue
slices were integrated on a single slide.
Detection of HNF4a and HNF3b in liver tissue specimen
by immunohistochemistry
In this study, immunohistochemistry was used to detect
expression levels of HNF4a and HNF3b in liver tissue spe-
cimens. Paraffin sections were deparaffinized, rehydrated
and incubated with 30 ml/L H2O2 at 37°C for 15 min.
Antigen retrieval was achieved using Supersonic wave
repair for 30 sec (for detection of HNF4a) or microwave
repair for 3 times plus Supersonic wave repair for 30 sec
(for detection of HNF3b). Incubation with primary antibo-
dies was performed at 37°C for 1 h and 4°C overnight, fol-
lowed by three washes with phosphate-buffered saline
(PBS). The primary antibodies used to detect the expres-
sion of HNF4a and HNF3b were goat anti-human HNF4a
polyclonal antibody (1:50 diluted) (Santa Cruz, USA), and
goat anti-human HNF3b polyclonal antibody (1:30
diluted) (Santa Cruz, USA), respectively. All sections were
then incubated with biotin-labeled secondary antibodies
including rabbit anti-goat IgG. After washing 3 times with
P B S ,t h ei m m u n ec o m p l e x e si nt h es p e c i m e n sw e r e
detected using DAB Substrate Kit (Wuhanboster Biologi-
cal Technology, China) according to the manufacture’s
instructions. The slides were then counterstained with
hematoxylin before being mounted.
Immunohistochemical scoring criteria
The immunohistochemical results of integrated tissue slice
slides were read independently by two pathologists who
had no prior knowledge of the experimental procedures.
The percentage of positive cells and the positive staining
intensity were checked and scored using the Axiotis score
standard by observation of 5 randomly chosen fields at
400-fold magnification. Sections detected by immunohis-
tochemistry were stained with DAB and conterstained
with hematoxylin, and positive signals were manifested as
yellow, brown, or tan staining. The scoring criteria
for the proportion of positive cells were: 0 = 0%-10% posi-
tive cells; 1 = 11%-25% positive cells; 2 = 26%-50% positive
cells; 3 = 51%-75% positive cells; 4 = 76%-100% positive
cells. The scoring criteria for staining intensity in positive
cells were: 0 = no color, 1 = yellow, 2 = brown, 3 = tan.
The sum of the scores for proportion of positive cells and
staining intensity was the final score for the sample. If the
film-reading results of the two pathologists were different
for the same sample, we then used the mean of the scores
to generate the final result.
Statistical analysis
The scores of HNF4a and HNF3b in specimens in each
group were presented as mean, and data were analyzed
using the SPSS version 13.0 software package (SPSS,
I n c . ,C h i c a g o ,I L ) .T e s t so fsignificance were 2-tailed,
with significance being indicated by a P-value < 0.05.
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